Prof. Dr. J. Rech

Publikationen: Prof. Dr. med. J. Rech

Friedrich R, Kernder A, Blank N, Ernst D, Henes J, Keyßer G, Klemm P, Krusche M, Meinecke A, Rech J, Schulz N, Schomburg D, Vordenbäumen S, Feist E: Implementation of the new DGRh S2e guideline on diagnostics and treatment of adult-onset Still's disease in Germany : Implications for clinical practice in rheumatology. Z Rheumatol. 2025;84(1): 30-38
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber AJ, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler DM, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester GR, Karberg K, Strunk J, Cañete JD, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino MA, Østergaard M, Schett G: Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403(10429): 850-859
Rech J, Schett G, Tufan A, Kuemmerle-Deschner JB, Özen S, Tascilar K, Geck L, Krickau T, Cohen E, Welzel T, Kuehn M, Vetterli M: Patient Experiences and Challenges in the Management of Autoinflammatory Diseases-Data from the International FMF &amp; AID Global Association Survey. J Clin Med. 2024;13(5):
Topping J, Chang L, Nadat F, Poulter JA, Ibbotson A, Lara-Reyna S, Watson CM, Carter C, Pournara LP, Zernicke J, Ross RL, Cargo C, Lyons PA, Smith KGC, Del Galdo F, Rech J, Fautrel B, Feist E, McDermott MF, Savic S, ImmunAID Consortium: Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease. Arthritis Rheumatol. 2024;():
Blank N, Kötter I, Schmalzing M, Rech J, Krause K, Köhler B, Kaudewitz D, Nitschke M, Haas CS, Lorenz HM, Krusche M: Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry. Rheumatol Int. 2024;44(2): 263-271
Reuner M, Krehbiel J, Rech J, Greiner B, Schäfer I, Herold R, Morawa E, Erim Y: Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome. BMC Public Health. 2024;24(1):
Coppers B, Bayat S, Tascilar K, Bohr D, Valor L, Simon D, Fagni F, Corte G, Hueber A, Morf H, Schoenau V, Sticherling M, Manger E, Liehr S, Rech J, Schett G, Kleyer A, Liphardt AM, Coppers B, Bayat S: Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study Arthritis Rheumatol. 2024;76 Suppl 9(): 4704-4707
Rech J, Hess A, Tascilar K, Schenker H, Schonau V, Sergeeva M, Prade J, Kreitz S, Sulvakumar M, Konerth L, Strobelt S, Englbrecht M, Hueber A, Feist E, Zaiss M, Burmester G, Behrens F, Koehm M, Baerwald C, Finzel S, Kleyer A, Voll R, Roesch J, Doerfler A, Damjanov N, Da Silva JAP, Schett G: Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients - "The PreCePRA Study" Arthritis Rheumatol. 2024;76 Suppl 9(): 1833-1836
Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T: Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis. Z Rheumatol. 2024;83(2): 142-150
Haschka J, Simon D, Bayat S, Messner Z, Kampylafka E, Fagni F, Skalicky S, Hackl M, Resch H, Zwerina J, Kleyer A, Cavallaro A, Sticherling M, Schett G, Kocijan R, Rech J: Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis. Rheumatology (Oxford). 2023;62(10): 3448-3458
Valor-Méndez L, Sticherling M, Zeschick M, Atreya R, Schmidt FD, Waldfahrer F, Saake M, Hüffmeier U, Schett G, Rech J: VEXAS syndrome mimicking lupus-like disease. Rheumatology (Oxford). 2023;62(9): e271-e272
Stephan M, Tascilar K, Yalcin-Mutlu M, Hagen M, Haschka J, Reiser M, Hartmann F, Kleyer A, Hueber AJ, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J: Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. J Clin Med. 2023;12(11):
Dand N, Stuart PE, Bowes J, Ellinghaus D, Nititham J, Saklatvala JR, Teder-Laving M, Thomas LF, Traks T, Uebe S, Assmann G, Baudry D, Behrens F, Billi AC, Brown MA, Burkhardt H, Capon F, Chung R, Curtis CJ, Duckworth M, Ellinghaus E, FitzGerald O, Gerdes S, Griffiths CEM, Gulliver S, Helliwell P, Ho P, Hoffmann P, Holmen OL, Huang ZM, Hveem K, Jadon D, Köhm M, Kraus C, Lamacchia C, Lee SH, Ma F, Mahil SK, McHugh N, McManus R, Modalsli EH, Nissen MJ, Nöthen M, Oji V, Oksenberg JR, Patrick MT, Perez-White BE, Ramming A, Rech J, Rosen C, Sarkar MK, Schett G, Schmidt B, Tejasvi T, Traupe H, Voorhees JJ, Wacker EM, Warren RB, Wasikowski R, Weidinger S, Wen X, Zhang Z, BSTOP study group , Estonian Biobank research team , Barton A, Chandran V, Esko T, Foerster J, Franke A, Gladman DD, Gudjonsson JE, Gulliver W, Hüffmeier U, Kingo K, Kõks S, Liao W, Løset M, Mägi R, Nair RP, Rahman P, Reis A, Smith CH, Di Meglio P, Barker JN, Tsoi LC, Simpson MA, Elder JT: GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. medRxiv. 2023;():
Vordenbäumen S, Feist E, Rech J, Fleck M, Blank N, Haas JP, Kötter I, Krusche M, Chehab G, Hoyer B, Kiltz U, Fell D, Reiners J, Weseloh C, Schneider M, Braun J: Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline. Z Rheumatol. 2023;82(Suppl 2): 81-92
Geck L, Tascilar K, Simon D, Kleyer A, Schett G, Rech J: Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases. J Clin Med. 2023;12(24):
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F, MUST Investigator Group , Alten RHE, Benesova K, Bergner R, Braun J, Demary W, Finzel S, Kästner P, Kleye A, Krüger K, Lorenz G, Max R, Poddubnyy D, Rubbert-Roth A, Schwenke H, Sieburg M, Thaci D, Thiele A, Voll RE, von Hinüber U, Walter J, Wassenberg S: Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol.. 2023;5(1): e14-e23
Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Burmester GR, Kofler DM, Brandt J, Finzel S, Bergner R, Sieburg M, Behrens F, MUST Investigator Group , Alten RH, Behrens F, Benesova K, Bergner R, Burmester GR, Brandt-Jürgens J, Braun J, Demary W, Finzel S, Kästner P, Kellner H, Kleye A, Kofler D, Krüger K, Lorenz G, Max R, Poddubnyy D, Rech J, Rubbert-Roth A, Schwenke H, Sieburg M, Thaçi D, Thiele A, Voll RE, von Hinüber U, Walter J, Wassenberg S: Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial. RMD Open. 2023;9(4):
Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Finzel S, Andreica I, Kofler DM, Weiner SM, Lamprecht P, Schulze-Koops H, App C, Pournara E, Mendelson MH, Sieder C, Maricos M, Thiel J: Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol.. 2023;5(6): e341-e350
Lorenz G, Schaaf C, Moog P, Bachmann Q, Popp F, Rech J, Schorr J, Gabl C, Küchle C, Delbridge C, Weirich GG, Heemann U, Schneider G, Lange N, Wagner M, Berg-Johnson W: Brain oedema due to disseminated intravascular coagulation in a patient with adult-onset Still's disease-associated hemophagocytic lymphohistiocytosis-a case report. Rheumatology (Oxford). 2023;62(6): e188-e190
Vordenbäumen S, Feist E, Rech J, Fleck M, Blank N, Haas JP, Kötter I, Krusche M, Chehab G, Hoyer B, Kiltz U, Fell D, Reiners J, Weseloh C, Schneider M, Braun J: Erratum to: Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline. Z Rheumatol. 2023;82(Suppl 2): 93-94
Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T: Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. Rheumatology (Oxford). 2023;62(4): 1476-1484
Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, Leipe J: High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. Mod Rheumatol. 2022;32(1): 87-95
Sokolova MV, Hagen M, Bang H, Schett G, Rech J, Steffen U, RETRO study group.: IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(5): 2124-2131
Wagner N, Manger B, Kittler J, Rech J, Sticherling M, Berking C, Kirchberger MC: Three generations of suffering: cryopyrin-associated periodic syndrome with NLRP3 mutation in a family. J Dtsch Dermatol Ges. 2022;20(1): 110-112
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Sokolova M, Zekovic A, Hueber AJ, Rech J, Schuster L, Engel K, Sticherling M, Schett G: Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis Rheumatol. 2022;74(2): 253-262
Simon D, Kleyer A, Bui CD, Hueber A, Bang H, Ramming A, Rech J, Schett G: Microstructural Bone Changes Are Associated With Broad-Spectrum Autoimmunity and Predict the Onset of Rheumatoid Arthritis. Arthritis Rheumatol. 2022;74(3): 418-426
Pachowsky ML, Raimondo MG, Xu C, Rauber S, Tascilar K, Labinsky H, Vogg M, Aziz Saad MS, Simon D, Rech J, Soare A, Braeuer L, Kleyer A, Schett G, Ramming A: Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients. Ann Rheum Dis. 2022;81(8): 1131-1135
Rech J, Schett G: Towards preventive treatment of rheumatoid arthritis. Lancet. 2022;400(10348): 253-255
Vordenbäumen S, Feist E, Rech J, Fleck M, Blank N, Haas JP, Kötter I, Krusche M, Chehab G, Hoyer B, Kiltz U, Fell D, Reiners J, Weseloh C, Schneider M, Braun J: [Guideline report on the DGRh S2e guidelines on diagnostics and treatment of adult-onset Still's disease (AOSD)]. Z Rheumatol. 2022;81(Suppl 1): 21-27
Vordenbäumen S, Feist E, Rech J, Fleck M, Blank N, Haas JP, Kötter I, Krusche M, Chehab G, Hoyer B, Kiltz U, Fell D, Reiners J, Weseloh C, Schneider M, Braun J: [DGRh S2e guidelines : Diagnostic and treatment of adult-onset Still's disease (AOSD)]. Z Rheumatol. 2022;81(Suppl 1): 1-20
Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022;61(7): 2915-2922
Vodencarevic A, Tascilar K, Hartmann F, Reiser M, Hueber AJ, Haschka J, Bayat S, Meinderink T, Knitza J, Mendez L, Hagen M, Krönke G, Rech J, Manger B, Kleyer A, Zimmermann-Rittereiser M, Schett G, Simon D, RETRO study group: Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021;23(1):
Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, Zhu X, James D, Martin R, Ligozio G, Abrams K, Pricop L: Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. J Clin Rheumatol. 2021;27(6): 239-247
Haskamp S, Horowitz JS, Oji V, Philipp S, Sticherling M, Schäkel K, Schuhmann S, Prinz JC, Burkhardt H, Behrens F, Böhm B, Köhm M, Rech J, Simon D, Schett G, Morrison K, Gerdes S, Assmann G, Nimeh A, Schuster V, Jacobi A, Weyergraf A, Reis A, Uebe S, Wilsmann-Theis D, Mößner R, Hüffmeier U: Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany. J Invest Dermatol. 2021;141(8): 2079-2083
Schönau V, Roth J, Tascilar K, Corte G, Manger B, Rech J, Schmidt D, Cavallaro A, Uder M, Crescentini F, Boiardi L, Casali M, Spaggiari L, Galli E, Kuwert T, Versari A, Salvarani C, Schett G, Muratore F: Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology (Oxford). 2021;60(8): 3851-3861
Schenker HM, Tascilar K, Konerth L, Sergeeva M, Prade J, Strobelt S, Kleyer A, Simon D, Mendez L, Hagen M, Schönau V, Hueber A, Roesch J, Dörfler A, Hess A, Schett G, Rech J: Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study. Contemp Clin Trials Commun. 2021;22():
Valor-Méndez L, Kleyer A, Rech J, Manger B, Schett G: Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis. Auto Immun Highlights. 2021;12(1):
Valor-Méndez L, Manger B, Cavallaro A, Achenbach S, Schett G, Rech J: Autoinflammation leading to autoimmunity in adult-onset Still's disease: more than simple coincidence? Eur J Med Res. 2021;26(1):
Valor-Méndez L, Tascilar K, Simon D, Distler J, Kleyer A, Schett G, Rech J: Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Ann Rheum Dis. 2021;80(10):
O'Neil LJ, Hu P, Liu Q, Islam MM, Spicer V, Rech J, Hueber A, Anaparti V, Smolik I, El-Gabalawy HS, Schett G, Wilkins JA: Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis. Front Immunol. 2021;12():
Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, Horneff G, Foeldvari I, Schuetz C, Borte M, Braner A, Weber-Arden J, Blank N: LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY Ann Rheum Dis. 2021;80 Suppl 1(): 50-51
Hagen M, Tascilar K, Reiser M, Valor L, Haschka J, Kleyer A, Hueber A, Manger B, Cobra J, Figuereido C, Finzel S, Tony HP, Wendler J, Kleinert S, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Alten R, Henes J, Krueger K, Rech J, Schett G: TREATMENT TAPERING AND WITHDRAWAL IN RHEUMATOID ARTHRITIS WITH STABLE REMISSION - FINAL ANALYSIS OF THE RETRO STUDY Ann Rheum Dis. 2021;80 Suppl 1(): 194-195
Tascilar K, Hagen M, Kleyer A, Simon D, Reiser M, Hueber AJ, Manger B, Englbrecht M, Finzel S, Tony HP, Schuch F, Kleinert S, Wendler J, Ronneberger M, Figueiredo CP, Cobra JF, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Kruger K, Henes J, Schett G, Rech J: Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial Lancet Rheumatol.. 2021;3(11): E767-E777
Sokolova MV, Rech J, Hagen M, Schett G, Steffen (Nee Harre) U: ASSOCIATION OF ANTI-CITRULLINATED PROTEIN ANTIBODIES OF IgA SUBCLASSES WITH SUSTAINED REMISSION AND FLARE IN RHEUMATOID ARTHRITIS Ann Rheum Dis. 2021;80 Suppl 1(): 461-461
Bleckwedel-Rolack L, Tascilar K, Nees V, Huehne J, Hueber A, Rech J, Schett G, Kleyer A, Liphardt AM: PATIENTS AT RISK FOR RA SHOW THE SAME AMOUNT OF ACUTE SOLUBLE CARTILAGE DEGRADATION MARKERS AFTER PHYSICAL ACTIVITY COMPARED TO PATIENTS WITH ESTABLISHED RA Ann Rheum Dis. 2021;80 Suppl 1(): 420-421
Valor-Méndez L, Kleyer A, Rech J, Manger B, Schett G: Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment. Rheumatology (Oxford). 2021;60(5): e162-e164
Valor-Méndez L, Voskens C, Rech J, Kleyer A, Schett G: Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report. Rheumatology (Oxford). 2021;60(4): e122-e123
Tascilar K, Simon D, Liphardt AM, Meinderink T, Bayat S, Rech J, Hueber A, Kroenke G, Schett G, Kleyer A: SPATIOTEMPORAL DYNAMICS OF BONE LOSS BEFORE AND AFTER THE ONSET OF RHEUMATOID ARTHRITIS Ann Rheum Dis. 2021;80 Suppl 1(): 88-89
Rech J, Sticherling M, Stoessel D, Biermann MHC, Häberle BM, Reinhardt M: Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. 2020;4(2):
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S, FUTURE 1 study group: Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2(1): 18-25
Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J: Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits Arthritis Rheumatol. 2020;72(1): 150-156
Steffen U, Koeleman CA, Sokolova MV, Bang H, Kleyer A, Rech J, Unterweger H, Schicht M, Garreis F, Hahn J, Andes FT, Hartmann F, Hahn M, Mahajan A, Paulsen F, Hoffmann M, Lochnit G, Munoz LE, Wuhrer M, Falck D, Herrmann M, Schett G: IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020;11(1):
Dürholz K, Hofmann J, Iljazovic A, Häger J, Lucas S, Sarter K, Strowig T, Bang H, Rech J, Schett G, Zaiss MM: Dietary Short-Term Fiber Interventions in Arthritis Patients Increase Systemic SCFA Levels and Regulate Inflammation. Nutrients. 2020;12(10):
Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, Schoenau V, Prade J, Sergeeva M, Sulvakumar M, Strobelt S, Konerth L, Behrens F, Baerwald C, Finzel S, Voll R, Hueber A, Roesch J, Feist E, da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) Arthritis Rheumatol. 2020;72 Suppl 10():
Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, Simon D, Rech J, Sticherling M, Schett G, Hueber A: Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis Arthritis Rheumatol. 2020;72 Suppl 10():
Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber A: Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function Arthritis Rheumatol. 2020;72 Suppl 10():
Rech J, Schenker H, Tascilar K, Hagen M, Mendez LV, Schoenau V, Sergeeva M, Prade J, Sulvakumar M, Konert L, Kleyer A, Simon D, Strobelt S, Behrens F, Baerwald C, Finzel S, Voll R, Hueber A, Feist E, Roesch J, da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial Arthritis Rheumatol. 2020;72 Suppl 10():
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, Schuster L, Engel K, Sticherling M, Schett G: Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis - A Prospective Cohort Study Arthritis Rheumatol. 2020;72 Suppl 10():
Hueffmeier UD, Loehr S, Uebe S, Popp B, Bowes J, Kirchner P, Giardina E, Korendowych E, Ekici AB, Ho P, Behrens F, Koehm M, Schett G, Rech J, Assmann G, Nimeh A, Padyukov L, Alenius G, McHugh NJ, Sticht H, Burkhardt H, Barton A, Reis A: Common RUNX3 missense variant contributes to psoriatic arthritis by affecting splicing and modifying signaling, activation and differentiation of T-cells Eur J Hum Genet. 2020;28 Suppl 1(SUPPL 1): 314-315
Simon D, Haschka J, Muschitz C, Kocijan A, Baierl A, Kleyer A, Schett G, Kapiotis S, Resch H, Sticherling M, Rech J, Kocijan R: Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis. Osteoporos Int. 2020;31(5): 931-939
Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, Simon D, Rech J, Sticherling M, Schett G, Hueber AJ: Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis. Arthritis Res Ther. 2020;22(1):
Frey S, Sticht H, Wilsmann-Theis D, Gerschütz A, Wolf K, Löhr S, Haskamp S, Frey B, Hahn M, Ekici AB, Uebe S, Thiel C, Reis A, Burkhardt H, Behrens F, Köhm M, Rech J, Schett G, Assmann G, Kingo K, Kõks S, Mössner R, Prinz JC, Oji V, Schulz P, Muñoz LE, Kremer AE, Wenzel J, Hüffmeier U: Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. J Invest Dermatol. 2020;140(7): 1451-1455.e13
Simon D, Tascilar K, Unbehend S, Bayat S, Berlin A, Liphardt AM, Meinderink T, Rech J, Hueber AJ, Schett G, Kleyer A: Bone Mass, Bone Microstructure and Biomechanics in Patients with Hand Osteoarthritis. J Bone Miner Res. 2020;35(9): 1695-1702
Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, Rech J, Schett G: A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):
Friedberger A, Figueiredo C, Grimm A, d'Oliveira I, Bäuerle T, Rech J, Kleyer A, Simon D, Uder M, Schett G, Engelke K: Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. BMC Musculoskelet Disord. 2020;21(1):
Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, Schuster L, Engel K, Sticherling M, Schett G: STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY Ann Rheum Dis. 2020;79 Suppl 1(): 33-34
Raimondo MG, Rauber S, Luber M, Rigau AR, Weber S, Anchang CG, Agarwal R, Soare A, Sticherling M, Rech J, Kleyer A, Distler J, Schett G, Ramming A: TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS Ann Rheum Dis. 2020;79 Suppl 1(): 1119-1120
Bayat S, Simon D, Pecherstorfer C, Ellmann H, Figueiredo C, Englbrecht M, Hueber A, Kleyer A, Rech J, Schett G: FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT Ann Rheum Dis. 2020;79 Suppl 1(): 1232-1232
Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Schonau V, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Baerwald C, Finzel S, Voll R, Feist E, Da Silva JAP, Doerfler A, Damjanov N, Hess A, Schett G: LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 77-78
Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Da Silva JAP, Baerwald C, Finzel S, Voll R, Feist E, Doerfler A, Damjanov N, Hess A, Schett G: CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 135-136
Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, Strobelt S, Hagen M, Schonau V, Valor L, Hueber A, Simon D, Kleyer A, Behrens F, Da Silva JAP, Baerwald C, Finzel S, Voll R, Feist E, Doerfler A, Damjanov N, Hess A, Schett G: PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) Ann Rheum Dis. 2020;79 Suppl 1(): 952-952
Renner N, Kleyer A, Krönke G, Simon D, Söllner S, Rech J, Uder M, Janka R, Schett G, Welsch GH, Pachowsky ML: T2 Mapping as a New Method for Quantitative Assessment of Cartilage Damage in Rheumatoid Arthritis. J Rheumatol. 2020;47(6): 820-825
Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes SA, Griep E, Harrison S, Gupta A, Lloyd-Hughes J, Roberts A, Layton M, Nowak NA, Patel J, Rech J, Smith JE, Watts S, Takt PP: Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial Lancet Rheumatol.. 2020;2(10): E623-E632
Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber AJ: Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function. ACR Open Rheumatol. 2020;2(12): 734-740
Pecherstorfer C, Simon D, Unbehend S, Ellmann H, Englbrecht M, Hartmann F, Figueiredo C, Hueber A, Haschka J, Kocijan R, Kleyer A, Schett G, Rech J, Bayat S: A Detailed Analysis of the Association between Urate Deposition and Erosions and Osteophytes in Gout. ACR Open Rheumatol. 2020;2(10): 565-572
Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Noelle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zaenker M, Hellmich B: S2k guidelines: management of large-vessel vasculitis Z Rheumatol. 2020;79 Suppl 3(SUPPL 3): 67-95
Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Noelle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zaenker M, Hellmich B: [S2k guidelines (executive summary): management of large-vessel vasculitis]. Z Rheumatol. 2020;79(9): 937-942
Pinter A, Kokolakis G, Rech J, Biermann MHC, Häberle BM, Multmeier J, Reinhardt M: Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. Dermatol Ther (Heidelb). 2020;10(4): 721-734
Rossmanith T, Koehm M, Kiltz U, Rech J, Burmester GR, Kellner H, Bulczak-Schadendorf A, Foldenauer AC, Burkhardt H, Behrens F: IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 773-773
Birkner B, Rech J, Stargardt T: Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE. 2020;15(1):
Stone JH, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 1077-1078
Stone JH, Neumann T, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Time to Flare in Patients With New-Onset Versus Relapsing Giant Cell Arteritis Treated With Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results From a Randomized Controlled Phase 3 Trial Swiss Med Wkly. 2020;(): 5S-5S
Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 20-20
Mclnnes LB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L: Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study Lancet Rheumatol.. 2020;2(4): E227-E235
Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S: LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL Ann Rheum Dis. 2019;78 Suppl 2(): 145-146
Moosig F, Schmalzing M, Aries PM, Henes J, Lamprecht P, Rech J, Witte T: [Actual Treatment Options for Giant Cell Arteritis]. Dtsch Med Wochenschr. 2019;144(9): 595-600
Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, Brandt-Jürgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, Köhler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hinüber U, Wagener P, Weidemann HF, Zinke S, Witte T: Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(5): 729-735
Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J, Schett G: Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4): 632-637
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid M, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony S, Collinson N: EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL Rheumatology (Oxford). 2019;58():
Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, Kleyer A, Schett G, Sticherling M, Hueber AJ: Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab J Dtsch Dermatol Ges. 2019;17(): 127-128
Simon D, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Liphardt AM, Rech J, Hueber A, Schett G, Kleyer A: EFFECT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON BONE STRUCTURE AND STRENGTH IN PSORIATIC ARTHRITIS PATIENTS Ann Rheum Dis. 2019;78(): 1287-1287
Rech J, Sticherling M, Biermann M, Haeberle B, Reinhardt M: Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis Arthritis Rheumatol. 2019;71 Suppl 10():
Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M: Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial Arthritis Rheumatol. 2019;71 Suppl 10():
Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S: Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
McInnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra S, Ding K, Ilsley E, Pricop L: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: LONG-TERM (4-YEAR) DATA FROM A PHASE 3 STUDY J Clin Rheumatol. 2019;25 Suppl 3(): S5-S5
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL Ann Rheum Dis. 2019;78 Suppl 2(): 917-917
Neumann T, Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH: Long-term outcome of tocilizumab for patients with giant cell arteritis: Results from part 2 of the GiACTA trial Swiss Med Wkly. 2019;(): 15S-15S
Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL Rheumatology (Oxford). 2019;58 Suppl 3(): 151-151
Gottlieb A, Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Ruvie M, Ligozio G, Abrams K, Pricop L: Seculdnumab efficacy in psoriatic arthritis: individual patient meta analysis of four phase 3 trials in 2049 patients J Eur Acad Dermatol Venereol. 2019;33 Suppl 3(): 83-84

Schriftgröße anpassen

Publikationen: Prof. Dr. med. J. Rech

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre